REAL

Analysis of EGFR Gene Amplification, Protein Over-expression and Tyrosine Kinase Domain Mutation in Recurrent Glioblastoma

Toth, Judit and Egervari, Kristof and Klekner, Almos and Bognar, Laszlo and Szanto, Janos and Nemes, Zoltan and Szollosi, Zoltan (2009) Analysis of EGFR Gene Amplification, Protein Over-expression and Tyrosine Kinase Domain Mutation in Recurrent Glioblastoma. Pathology and Oncology Research, 15 (2). pp. 225-229. ISSN 1219-4956

[img] Text
Analysis of EGFR Gene Amplification, Protein Over-expression and Tyrosine Kinase Domain Mutation in recurrent Glioblastoma.pdf
Restricted to Registered users only

Download (219kB) | Request a copy

Abstract

Abstract Gefitinib and erlotinib are both selective EGFR tyrosine kinase inhibitors (EGFR-TKIs) that have produced responses in a small subgroup of lung cancer patients. The strongest evidence for a role of EGFR in the biology of glioblastoma stems from clinical trials in which 15–20% of recurrent glioblastoma patients experienced significant tumour regression in response to these small-molecule EGFR kinase inhibitors. We examined the protein-kinase domain of the EGFR gene, EGFR protein expression and EGFR gene amplification in 20 cases of recurrent GBMs. EGFR protein over-expression was found in 65% of cases. EGFR protein over-expression was associated with EGFR gene amplification in 35% of cases, and with high polysomy in 15% of cases. No mutations were found in the TK domain of the EGFR gene. Our results confirm that mutations in the kinase domain are absent in recurrent GBM, and this might be a preponderant factor in the lack of major clinical responses of TKIs in GBM, recent studies have suggested that responsiveness to EGFR kinase inhibitors was strongly associated with coexpression of EGFRvIII and PTEN. Further prospective validation of EGFRvIII and PTEN as predictors of the clinical response to EGFR kinase inhibitors in recurrent GBM is strongly anticipated.

Item Type: Article
Uncontrolled Keywords: Glioblastoma multiforme, EGFR, Kinase inhibitor treatment
Subjects: R Medicine / orvostudomány > RC Internal medicine / belgyógyászat > RC0254 Neoplasms. Tumors. Oncology (including Cancer) / daganatok, tumorok, onkológia
Depositing User: Dr. Álmos Klekner
Date Deposited: 26 Sep 2014 18:12
Last Modified: 26 Sep 2014 18:12
URI: http://real.mtak.hu/id/eprint/15922

Actions (login required)

Edit Item Edit Item